

# David R Hessel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4052742/publications.pdf>

Version: 2024-02-01

77  
papers

5,722  
citations

81743

39  
h-index

79541

73  
g-index

78  
all docs

78  
docs citations

78  
times ranked

3318  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in the Treatment of Fragile X Syndrome. <i>Pediatrics</i> , 2009, 123, 378-390.	1.0	513
2	Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X Premutation. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2006, 27, S137-S144.	0.6	292
3	Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial. <i>Science Translational Medicine</i> , 2012, 4, 152ra127.	5.8	289
4	Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. <i>Journal of Neurodevelopmental Disorders</i> , 2011, 3, 57-67.	1.5	269
5	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 280-299.	21.5	247
6	Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 139B, 115-121.	1.1	215
7	Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.. <i>Neuropsychology</i> , 2008, 22, 48-60.	1.0	167
8	Lifetime Prevalence of Mood and Anxiety Disorders in Fragile X Premutation Carriers. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 175-182.	1.1	162
9	A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2009, 1, 33-45.	1.5	156
10	A Review of Fragile X Premutation Disorders. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 852-862.	1.1	154
11	The neuroanatomy and neuroendocrinology of fragile X syndrome. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2004, 10, 17-24.	3.5	137
12	Outcome Measures for Clinical Trials in Fragile X Syndrome. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2013, 34, 508-522.	0.6	136
13	Progression of tremor and ataxia in male carriers of the FMR1 premutation. <i>Movement Disorders</i> , 2007, 22, 203-206.	2.2	134
14	Amygdala dysfunction in men with the fragile X premutation. <i>Brain</i> , 2007, 130, 404-416.	3.7	125
15	Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2017, 9, 14.	1.5	123
16	Factors Associated with Parenting Stress in Mothers of Children with Fragile X Syndrome. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2003, 24, 267-275.	0.6	120
17	A Review of Fragile X Premutation Disorders. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e1-e11.	1.1	119
18	Neurobehavioral phenotype in carriers of the fragile X premutation. <i>American Journal of Medical Genetics Part A</i> , 2001, 103, 314-319.	2.4	116

#	ARTICLE	IF	CITATIONS
19	Social behavior and cortisol reactivity in children with fragile X syndrome. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006, 47, 602-610.	3.1	111
20	Improving IQ measurement in intellectual disabilities using true deviation from population norms. <i>Journal of Neurodevelopmental Disorders</i> , 2014, 6, 16.	1.5	111
21	Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. <i>Neuropsychopharmacology</i> , 2018, 43, 503-512.	2.8	102
22	Fragile X targeted pharmacotherapy: lessons learned and future directions. <i>Journal of Neurodevelopmental Disorders</i> , 2017, 9, 7.	1.5	99
23	The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions. <i>Journal of Neurodevelopmental Disorders</i> , 2016, 8, 35.	1.5	96
24	Electrocortical changes associated with minocycline treatment in fragile X syndrome. <i>Journal of Psychopharmacology</i> , 2013, 27, 956-963.	2.0	92
25	Brief Report: Aggression and Stereotypic Behavior in Males with Fragile X Syndrome—Moderating Secondary Genes in a “Single Gene” Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2008, 38, 184-189.	1.7	89
26	Decreased Fragile X Mental Retardation Protein Expression Underlies Amygdala Dysfunction in Carriers of the Fragile X Premutation. <i>Biological Psychiatry</i> , 2011, 70, 859-865.	0.7	88
27	Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. <i>Movement Disorders</i> , 2007, 22, 645-650.	2.2	84
28	Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. <i>General Hospital Psychiatry</i> , 2007, 29, 349-356.	1.2	83
29	The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2008, 30, 853-869.	0.8	83
30	Brief Report: Visual Processing of Faces in Individuals with Fragile X Syndrome: An Eye Tracking Study. <i>Journal of Autism and Developmental Disorders</i> , 2009, 39, 946-952.	1.7	73
31	Prepulse inhibition in fragile X syndrome: Feasibility, reliability, and implications for treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 545-553.	1.1	68
32	fMRI Study of Cognitive Interference Processing in Females with Fragile X Syndrome. <i>Journal of Cognitive Neuroscience</i> , 2002, 14, 160-171.	1.1	67
33	A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2017, 9, 26.	1.5	67
34	Fragile X—Associated Tremor/Ataxia Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1022.	4.5	64
35	Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2011, 41, 1515-1522.	1.7	60
36	Reduced Hippocampal Activation During Recall is Associated with Elevated FMR1 mRNA and Psychiatric Symptoms in Men with the Fragile X Premutation. <i>Brain Imaging and Behavior</i> , 2008, 2, 105-116.	1.1	54

#	ARTICLE	IF	CITATIONS
37	Age-Dependent Structural Connectivity Effects in Fragile X Premutation. Archives of Neurology, 2012, 69, 482-9.	4.9	51
38	Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of Neurodevelopmental Disorders, 2012, 4, 2.	1.5	47
39	Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation. Neurobiology of Aging, 2017, 55, 11-19.	1.5	46
40	Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology, 2020, 94, e1229-e1240.	1.5	44
41	Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. Intractable and Rare Diseases Research, 2015, 4, 123-130.	0.3	39
42	Best Practices in Fragile X Syndrome Treatment Development. Brain Sciences, 2018, 8, 224.	1.1	37
43	Executive Function in Fragile X Syndrome: A Systematic Review. Brain Sciences, 2019, 9, 15.	1.1	31
44	Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities. Brain Sciences, 2019, 9, 18.	1.1	30
45	Extending the Parent-Delivered Early Start Denver Model to Young Children with Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2019, 49, 1250-1266.	1.7	27
46	Male Carriers of the FMR1 Premutation Show Altered Hippocampal-Prefrontal Function During Memory Encoding. Frontiers in Human Neuroscience, 2012, 6, 297.	1.0	25
47	The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery. Stem Cells Translational Medicine, 2014, 3, 1275-1286.	1.6	24
48	Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed. Journal of Neurodevelopmental Disorders, 2019, 11, 4.	1.5	23
49	Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome. PLoS ONE, 2019, 14, e0209984.	1.1	22
50	Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1139-1147.	1.1	21
51	Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. Brain Sciences, 2020, 10, 629.	1.1	21
52	Standardized Assessment Accommodations for Individuals with Intellectual Disability. Contemporary School Psychology, 2018, 22, 443-457.	0.9	19
53	Computerized Cognitive Training in Children With Autism and Intellectual Disabilities: Feasibility and Satisfaction Study. JMIR Mental Health, 2018, 5, e40.	1.7	18
54	Fragile X Syndrome: Psychiatric Manifestations, Assessment and Emerging Therapies. Current Psychiatry Reviews, 2013, 9, 53-58.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Middle Cerebellar Peduncle Widthâ€”A Novel MRI Biomarker for FXTAS?. <i>Frontiers in Neuroscience</i> , 2018, 12, 379.	1.4	16
56	Emergence of Developmental Delay in Infants and Toddlers With an <i>FMR1</i> Mutation. <i>Pediatrics</i> , 2021, 147, .	1.0	16
57	Aging in Fragile X Premutation Carriers. <i>Cerebellum</i> , 2016, 15, 587-594.	1.4	14
58	A feasibility trial of Cogmed working memory training in fragile X syndrome. <i>Journal of Pediatric Genetics</i> , 2015, 03, 147-156.	0.3	13
59	Clinical and molecular correlates in fragile X premutation females. <i>ENeurologicalSci</i> , 2017, 7, 49-56.	0.5	13
60	Ageâ€”and CGG repeatâ€”related slowing of manual movement in fragile X carriers: A prodrome of fragile Xâ€”associated tremor ataxia syndrome?. <i>Movement Disorders</i> , 2018, 33, 628-636.	2.2	13
61	Presence of Middle Cerebellar Peduncle Sign in <i>FMR1</i> Premutation Carriers Without Tremor and Ataxia. <i>Frontiers in Neurology</i> , 2018, 9, 695.	1.1	13
62	Women with Fragile Xâ€”associated Tremor/Ataxia Syndrome. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 910-919.	0.8	13
63	Soy-Based Infant Formula is Associated with an Increased Prevalence of Comorbidities in Fragile X Syndrome. <i>Nutrients</i> , 2020, 12, 3136.	1.7	13
64	Fear Potentiated Startle in Children With Autism Spectrum Disorder: Association With Anxiety Symptoms and Amygdala Volume. <i>Autism Research</i> , 2021, 14, 450-463.	2.1	12
65	Metabolic profiling reveals dysregulated lipid metabolism and potential biomarkers associated with the development and progression of Fragile Xâ€”Associated Tremor/Ataxia Syndrome (FXTAS). <i>FASEB Journal</i> , 2020, 34, 16676-16692.	0.2	11
66	<i>FMR1</i> locus isoforms: potential biomarker candidates in fragile X-associated tremor/ataxia syndrome (FXTAS). <i>Scientific Reports</i> , 2020, 10, 11099.	1.6	11
67	Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with <i>FMR1</i> normal and premutation alleles. <i>Neurobiology of Aging</i> , 2020, 86, 27-38.	1.5	10
68	Using the <i>NIH</i> Toolbox to Assess Cognition in Adolescents and Young Adults with Autism Spectrum Disorders. <i>Autism Research</i> , 2021, 14, 500-511.	2.1	9
69	Neuropsychological changes in <i>FMR1</i> premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, 23.	1.5	8
70	Fragile X-associated tremor/ataxia syndrome: another phenotype of the fragile X gene. <i>Clinical Neuropsychologist</i> , 2016, 30, 810-814.	1.5	7
71	Cognitive Training Deep Dive: The Impact of Child, Training Behavior and Environmental Factors within a Controlled Trial of Cogmed for Fragile X Syndrome. <i>Brain Sciences</i> , 2020, 10, 671.	1.1	7
72	Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation. <i>Frontiers in Neurology</i> , 2022, 13, 797649.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers. <i>Frontiers in Genetics</i> , 2018, 9, 302.	1.1	4
74	Assessing processing speed among individuals with intellectual and developmental disabilities: A match-to-sample paradigm. <i>Child Neuropsychology</i> , 2022, 28, 1-13.	0.8	3
75	Metabolomic Biomarkers Are Associated With Area of the Pons in Fragile X Premutation Carriers at Risk for Developing FXTAS. <i>Frontiers in Psychiatry</i> , 2021, 12, 691717.	1.3	2
76	Prosaccade and Antisaccade Behavior in Fragile X-associated Tremor/Ataxia Syndrome Progression. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 473-478.	0.8	1
77	The International Fragile X Premutation Registry: building a resource for research and clinical trial readiness. <i>Journal of Medical Genetics</i> , 0, , jmedgenet-2022-108568.	1.5	0